News

Galectin Therapeutics was issued a patent for its lead investigative therapy GR-MD-02 for the treatment of pulmonary fibrosis by the U.S. Patent and Trademark Office (USPTO), the company announced. GR-MD-02 is a carbohydrate-based medicine that binds and stops the action of the galectin-3 protein, which is directly involved in multiple…

The Pulmonary Fibrosis Foundation (PFF) has launched its Oxygen Information Line to provide information and resources to help people using supplemental oxygen and their caregivers. Using the line, people can get reliable advice about which oxygen delivery system to use, how to manage flow settings, and how to ensure safety.

A new, wireless home monitoring program designed to collect data on lung function from patients with idiopathic pulmonary fibrosis (IPF) in real time showed good results and was approved by patients in a Dutch pilot study. Findings showed that spirometry measurements, which assess the amount and/or speed of air inhaled…

The patientMpower digital healthcare app now offers a “share” tool that allows patients with pulmonary fibrosis and like conditions to easily keep caregivers, friends, and family members aware of their progress, according to a blog on the company’s website. The interactive mobile platform — the basis of the…

Serotonin — a chemical produced by nerve cells — aggravated pulmonary fibrosis by promoting inflammation, oxidative stress (an imbalance between the production of reactive oxygen species and antioxidant defenses), and activating fibrosis-associated genes in a mouse model of pulmonary fibrosis, a new study shows. The study, “Serotonin Exhibits Accelerated…

A plant compound called parthenolide significantly reduces lung fibrosis and its associated inflammatory responses, according to a study conducted in mice with idiopathic pulmonary fibrosis (IPF). The work also exposed the mechanisms behind parthenolide’s actions, providing a deeper understanding of lung fibrosis’ mechanisms and potential therapeutic targets. The study,…